Market disruptor BFKW is developing the Full Sense bariatric device with patent protection across US, EU, Australia, China and Russia, indicating a strong potential to disrupt traditional obesity treatments and create new sales opportunities with healthcare providers, hospitals and surgical centers.

Clinical progress The device has undergone preclinical evaluations and has been implanted in over 50 patients with zero non-responders and superior excess weight loss compared to gastric bypass and gastric banding, suggesting compelling value propositions for early adopter clinics and trial partnerships.

Strategic financing Recent financing of 2.1M demonstrates investor confidence and fundraising activity that could support expanded clinical trials, regulatory work, and accelerated sales efforts targeting endocrinology, bariatrics, and surgical device channels.

Technologies & partnerships Leveraging a digital and web presence alongside collaboration-ready platforms (GoDaddy, Microsoft 365, analytics tools) indicates readiness for marketing automation, physician outreach, and customer education programs to accelerate market uptake.

Growth opportunities With modest current revenue and a small team, there is potential to partner with contract research organizations, distributors, or major medical device distributors to scale clinical trials, regulatory activities, and commercialization in multiple jurisdictions.